# Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes

> **NCT01006291** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 687 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** insulin degludec
- **DRUG:** insulin degludec
- **DRUG:** insulin glargine

## Key facts

- **NCT ID:** NCT01006291
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 687 (ACTUAL)
- **Last updated:** 2017-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01006291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01006291, "Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01006291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*